Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting
- 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance®
- Abstracts on investigational empagliflozin/linagliptin combination tablet
- Data on Lilly/BI’s investigational insulin glargine product
- Abstracts on Trajenta® (linagliptin) and linagliptin in combination with metformin
Highlights of the presentations include:
△ Empagliflozin, recently approved in Europe and in the US: Safety and tolerability of empagliflozin, a sodium cotransporter 2 (SGLT2) inhibitor, in Phase III trials and their extensions in adults with T2D
△ Investigational empagliflozin/linagliptin combination tablet: 52 week efficacy and safety results from the investigational oral combinations of empagliflozin/linagliptin in treatment naïve adults with T2D and as add-on to metformin in adults with T2D
△ Lilly/BI’s investigational insulin glargine product: Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with Type 1 Diabetes (T1D): the ELEMENT 1 study
△ Lilly/BI’s investigational insulin glargine product: Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with T2D: the ELEMENT 2 study
△ Linagliptin: Safety results for the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in 8,778 adults with T2D from a pooled analysis of 23 placebo-controlled randomised clinical trials
△ Linagliptin/metformin: Efficacy of linagliptin in combination with metformin in adults with newly diagnosed T2D and marked hyperglycaemia
△ IntroDia™: Challenges faced by physicians during the diagnosis conversations in T2D management.
Empagliflozin data
A total of 13 clinical and non-clinical abstracts for empagliflozin will be presented. Empagliflozin, approved as Jardiance® in Europe and in the US, is an oral, once daily SGLT2 inhibitor for the treatment of adults with Type 2 Diabetes. SGLT2 inhibition reduces reabsorption of glucose into the bloodstream, allowing excess glucose to pass through the urine.1
Details of the key clinical presentations and posters are as follows:
△ Tuesday 16 September, 11:15-11:30, Oral Presentation: OP 01 SGLT2 inhibitors: new outcome studies
· Empagliflozin compared with glimepiride as add-on to metformin for 2 years in patients with Type 2 Diabetes (Lead Author: M. Ridderstråle) [Abstract No. 2]
△ Tuesday 16 September, 11:30-11:45, Oral Presentation: OP 01 SGLT2 inhibitors: new outcome studies
· Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition (Lead Author: G. Ferrannini) [Abstract No. 3]
△ Tuesday 16 September, 14:15, Poster Session: PS 062 SGLT2 inhibitors: non-glycaemic endpoints
· Effects of empagliflozin compared with glimepiride as add-on to metformin for 2 years on the amount and distribution of body fat in patients with type 2 diabetes (Lead Author: G. Kim) [Poster No. 818]
· Sodium glucose cotransporter 2 inhibition with empagliflozin reduces microalbuminuria in patients (Lead Author: D. Cherney) [Poster No. 823]
△ Wednesday 17 September, 14:15, Poster Session: PS 076 Glucose variability in insulin treatment
· Sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin (EMPA) in type 1 diabetes (T1D): impact on diurnal glycemic patterns (Lead Author: B.A. Perkins) [Poster No. 956]
△ Thursday 18 September, 13:00, Poster Session: PS 065 SGLT2 inhibitors: efficacy
· Empagliflozin twice daily versus once daily as add-on to metformin in patients with type 2 diabetes (Lead Author: S. Ross) [Poster No. 849]
△ Thursday 18 September, 14:15, Poster Session: PS 060 SGLT2 inhibitors: safety
· Safety and tolerability of empagliflozin (EMPA) in Phase III trials and their extensions in patients with Type 2 Diabetes (T2DM) (Lead Author: M. Roden) [Poster No. 806]
Investigational empagliflozin/linagliptin combination tablet
Two clinical abstracts for the investigational empagliflozin/linagliptin combination tablet will be presented.
Details of the key clinical presentation and poster are as follows:
△ Tuesday 16 September, 11:00-11:15, Oral Presentation: OP 01 SGLT2 inhibitors: new
outcome studies
· Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in patients with Type 2 Diabetes (Lead Author: S. Patel) [Abstract No. 1]
△ Thursday 18 September, 13:00, Poster session: PS 065 SGLT2 inhibitors: efficacy
· Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in drug-naïve patients with Type 2 Diabetes (Lead Author: A. Lewin) [Poster No. 851]
Lilly/Boehringer Ingelheim’s investigational insulin glargine data
A total of four clinical abstracts will be presented for Lilly/BI’s investigational insulin glargine product. This insulin glargine product is a basal insulin, which is intended to provide long-lasting blood sugar control between meals and at night in people with T1D and T2D.2
Details of the presentations and posters are as follows:
△ Tuesday 16 September, 14:15, Poster Session: PS 074 The potential future of insulin therapy
· Comparison of duration of action of 2 insulin glargine products, LY2963016 and insulin glargine, in subjects with Type 1 Diabetes Mellitus (Lead Author: H. Linnebjerg) [Poster No. 935]
△ Wednesday 17 September, 14:15, Poster Session: PS 076 Glucose variability in insulin treatment
· Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with Type 2 Diabetes Mellitus: the ELEMENT 2 study (Lead Author: P. Hollander) [Poster No. 948]
△ Thursday 18 September, 10:30-10:45, Oral Presentation: OP 25 Novel insulin formulations and combinations
· Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with Type 1 Diabetes Mellitus: the ELEMENT 1 study (Lead Author: R.K. Pollom) [Abstract No.146]
△ Thursday 18 September, 14:15, Poster Session: PS 078 Insulin immunogenicity and kinetics
· Evaluation of immunogenicity of LY2963016 insulin glargine compared with insulin glargine in patients with Type 2 Diabetes Mellitus (Lead Author: L. Ilag) [Poster No. 969]
Linagliptin data
A total of seven clinical and non-clinical abstracts for linagliptin will be presented. Linagliptin, marketed as Trajenta® in Europe, is a once-daily tablet used to improve blood glucose control in adults with T2D. Linagliptin is an inhibitor of the enzyme DPP-4 which breaks down the incretin hormones that are involved with regulating blood glucose.3
Details of the key clinical posters are as follows:
△ Tuesday 16 September, 13:00, Poster Session: PS 061 Insulin secretagogues
· Efficacy and safety of initial therapy with linagliptin + pioglitazone fixed-dose combinations versus monotherapy with pioglitazone or linagliptin (Lead author: S. Weber-Born) [Poster No. 815]
△ Wednesday 17 September, 13:00, Poster Session: PS 069 Safety of DPP-4 inhibitors
· Safety of linagliptin in 8778 patients with Type 2 Diabetes Mellitus: pooled analysis of 23 placebo-controlled randomised clinical trials (Lead Author: G. Schernthaner) [Poster No. 885]
Linagliptin and metformin data
One clinical abstract for linagliptin in combination with metformin will be presented.
Details of the clinical poster are as follows:
△ Wednesday 17 September, 14:15, Poster session: PS 070 Clinical studies with DPP-4 inhibitors
· Oral glucose lowering with linagliptin plus metformin is a viable initial treatment strategy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia (Lead Author: B. Gallwitz) [Poster No. 894]
IntroDia™
One abstract will be presented for IntroDia™, the largest global survey being conducted in partnership with the International Diabetes Federation. The survey is evaluating early treatment conversations in T2D management.
Details of the poster are as follows:
△ Tuesday 16 September, 14:15, Poster Session: PS 086 Psychology and quality of life
· Physicians’ challenges when discussing the T2D diagnosis with patients: insights from a cross-national study (IntroDia™) (Lead Author: W.H. Polonsky) [Poster No. 1030]
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/09_september_2014_diabetes.html
Website: http://www.boehringer-ingelheim.com
Contact
Boehringer Ingelheim GmbH
Ralph Warsinsky
Corporate Communications
+49 178 290 8561
press@boehringer-ingelheim.com
Lilly Diabetes
Tammy Hull
Communications Manager
+1 317 651 9116
hullta@lilly.com
This news is a press release provided by Boehringer Ingelheim International GmbH.
-
2021년 9월 10일 15:15
-
2021년 3월 2일 15:05